Evaluation of genetic variants for Type 2 diabetes associated kidney disease in African Americans

End-stage kidney disease (ESKD) is a significant public health problem in the U.S., disproportionately affecting African Americans (AAs; 1,003 per million/year) at 3.3-fold higher incidence rate than European Americans (301 per million/year), and 2-fold higher than Native Americans (499 per million/year) in 2014. Diabetic kidney disease (DKD), primarily attributed to type 2 diabetes (T2D), including ESKD and advanced chronic kidney disease (CKD) accounts for over 40% of all ESKD cases. Observation of familial aggregation in epidemiologic studies suggests that genetic factors may contribute to the risk of DKD. While apolipoprotein L1 gene (APOL1) G1 and G2 alleles explain approximately 70% of the disparity in non-diabetic ESKD in AAs, they fail to account for the excess risk of T2D-ESKD in AAs. Genetic studies have revealed >70 genome-wide significant of genetic determinants with impact on kidney diseases or kidney functions. Despite the progress, the proportion of T2D-ESKD susceptibility attributed by these kidney related genes is still unclear. The goal of this series of studies is to provide a comprehensive evaluation of the genetic architecture of T2D-ESKD in AAs.

Grantor dc:publisher

Wake Forest University

Year dc:date.issued

2017

Author dc:creator

• Guan, Meijian

• African Americans

Language dc:language.iso

en

Handle dc:identifier.uri

http://hdl.handle.net/10339/86347

OAI identifier oai:identifier

oai:wakespace.lib.wfu.edu:10339/86347